NS (and nobody else)
I had a conversation today with someone knowledgeable on the subject of Amarin. Very interesting. A very important point was made that I hadn’t considered: if Sarissa gets their 7 seats and PWO is removed then when the next AGM comes up, where the longest sitting 1/3 of board members are put up for reelection, it will all be current board members who are up for reelection. This will be an opportunity for Sarissa to remove the remaining board members and Denner will have complete control. Absolute control. WS knows this and a vote to add all 7 members will tank the stock as WS sees this as destabilizing the company. Senior Amarin staff in EU who are organizing the launch will see the writing on the wall and will start to abandon ship at the first opportunity. Denner and Sarissa have lots of experience “flipping” a company but their board nominees are completely unqualified to launch a new drug in EU. This person feels a Sarrisa controlled board would be under pressure to sell ASAP and a desperate sale is never a good sale for the seller.
This has all been very precisely timed by Denner. It explains why he waited until days before the last AGM to submit names and why he didn’t allow time for Amarin to interview the 7 current nominees. He never wanted just a few seats. His plan all along was to force a proxy fight for half the board a few months before the next AGM.
Denner is going for 100% and feeding shareholder frustrations by planting disinformation via Lizzy and others 20 times/day. Desperate and frustrated retails all falling in line behind him one after another simply believing “anything will be better” when he clearly has no real plan for change.
There is no question that Amarin ignored retail and now that is going to really bite them in the ass. They couldn’t post publicly without blocking responses because children like Raf, Garvey etc would post completely inappropriate comments and demand answers that couldn’t (or shouldn’t) be posted publicly. Raf is STILL demanding Amarin publicly state that Preston Mason couldn’t find a significant difference in purity between V and gV.
IP loss - not KM’s fault
Germany- completely a political & financial decision, not KM’s fault
Current EU launch/sales- industry standard, nothing unusual (Canada approval 3 years ago, sales just getting started)
US sales: no patents, no protection= market share should be around 10% but they have maintained 60% = miracle
Cash burn slashed, focused on EU (US courts are responsible for Americans not getting this life saving drug)
I’m back to voting white. I don’t see Sarissa bringing anything of value (Amarin has a top notch M&A guy now, they don’t need 7 more) and their tactics have all been “odd” and the timing suspicious.
If Amarin can maintain 50,000 scripts/week Q1 and Q2 then EU will slowly come online and once that happens WS will take notice.
7 Sarissa seats will tank this stock immediately. WS is ALWAYS 1 step ahead of retail and the opposite of what retail expects to happen is always what actually happens.
